These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 25239305)
1. The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials. Qian H; Gao F; Wang H; Ma F BMC Cancer; 2014 Sep; 14():683. PubMed ID: 25239305 [TBL] [Abstract][Full Text] [Related]
2. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer. O'Bryant CL; Wenger SD; Kim M; Thompson LA Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065 [TBL] [Abstract][Full Text] [Related]
3. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012 [TBL] [Abstract][Full Text] [Related]
4. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551 [TBL] [Abstract][Full Text] [Related]
5. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. Croegaert K; Kolesar JM Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238 [TBL] [Abstract][Full Text] [Related]
6. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Ou SH Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641 [TBL] [Abstract][Full Text] [Related]
7. ALK inhibitors in the treatment of advanced NSCLC. Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927 [TBL] [Abstract][Full Text] [Related]
8. Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis. Hu H; Qing Lin W; Zhu Q; Wen Yang X; Wang HD; Kuang YK Oncotarget; 2016 Dec; 7(49):81090-81098. PubMed ID: 27835601 [TBL] [Abstract][Full Text] [Related]
9. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Frampton JE Drugs; 2013 Dec; 73(18):2031-51. PubMed ID: 24288180 [TBL] [Abstract][Full Text] [Related]
10. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Shaw AT; Yeap BY; Solomon BJ; Riely GJ; Gainor J; Engelman JA; Shapiro GI; Costa DB; Ou SH; Butaney M; Salgia R; Maki RG; Varella-Garcia M; Doebele RC; Bang YJ; Kulig K; Selaru P; Tang Y; Wilner KD; Kwak EL; Clark JW; Iafrate AJ; Camidge DR Lancet Oncol; 2011 Oct; 12(11):1004-12. PubMed ID: 21933749 [TBL] [Abstract][Full Text] [Related]
11. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ou SH; Jänne PA; Bartlett CH; Tang Y; Kim DW; Otterson GA; Crinò L; Selaru P; Cohen DP; Clark JW; Riely GJ Ann Oncol; 2014 Feb; 25(2):415-22. PubMed ID: 24478318 [TBL] [Abstract][Full Text] [Related]
12. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Camidge DR; Bang YJ; Kwak EL; Iafrate AJ; Varella-Garcia M; Fox SB; Riely GJ; Solomon B; Ou SH; Kim DW; Salgia R; Fidias P; Engelman JA; Gandhi L; Jänne PA; Costa DB; Shapiro GI; Lorusso P; Ruffner K; Stephenson P; Tang Y; Wilner K; Clark JW; Shaw AT Lancet Oncol; 2012 Oct; 13(10):1011-9. PubMed ID: 22954507 [TBL] [Abstract][Full Text] [Related]
13. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500 [TBL] [Abstract][Full Text] [Related]
14. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies. Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017 [TBL] [Abstract][Full Text] [Related]
15. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T; N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279 [TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients. Cui S; Zhao Y; Gu A; Ge X; Song Y; Zhang W; Lou Y; Dong L; Han B; Jiang L Med Oncol; 2015 Jun; 32(6):626. PubMed ID: 25966792 [TBL] [Abstract][Full Text] [Related]
18. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. Ou SH; Ahn JS; De Petris L; Govindan R; Yang JC; Hughes B; Lena H; Moro-Sibilot D; Bearz A; Ramirez SV; Mekhail T; Spira A; Bordogna W; Balas B; Morcos PN; Monnet A; Zeaiter A; Kim DW J Clin Oncol; 2016 Mar; 34(7):661-8. PubMed ID: 26598747 [TBL] [Abstract][Full Text] [Related]
19. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Awad MM; Shaw AT Clin Adv Hematol Oncol; 2014 Jul; 12(7):429-39. PubMed ID: 25322323 [TBL] [Abstract][Full Text] [Related]
20. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. Lei YY; Yang JJ; Zhang XC; Zhong WZ; Zhou Q; Tu HY; Tian HX; Guo WB; Yang LL; Yan HH; Chen HJ; Xie Z; Su J; Han JF; Wu YL Clin Lung Cancer; 2016 May; 17(3):223-31. PubMed ID: 26454342 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]